• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Mylan Pharma rolls out muscle relaxant drug

      Posted Atdrugdiscovery.pharmaceutical-business-review.com

      AstraZeneca has received the US Food and Drug Administration's (FDA) approval for the use of Nexium I.V. (Esomeprazole sodium) for injection for the treatment of children 1 month to 17 years old who are suffering from gastroesophageal reflux disease (GERD) with erosive esophagitis.

      Nexium I.V. is a proton pump inhibitor indicated for the treatment of GERD with erosive esophagitis in adults and pediatric patients greater than one month of age, when oral therapy is not possible or appropriate.

      AstraZeneca Gastrointestinal Disorders executive director Marta Illueca said this approval represents an important contribution to an unmet medical need for infants in particular.

      "While some reflux and regurgitation are normal in infants and may not require medical treatment, persistent GERD symptoms can be very uncomfortable and cause damage to the esophagus, just as they can in older patients," Illueca said.

      May 18, 2011


      Share this Article!

    Back to top^